Compass Therapeutics (NASDAQ:CMPX) Stock Price Down 7.6% – Here’s Why

Compass Therapeutics, Inc. (NASDAQ:CMPX)’s share price was down 7.6% on Tuesday . The stock traded as low as $3.60 and last traded at $3.61. Approximately 1,262,924 shares changed hands during mid-day trading, a decline of 47% from the average daily volume of 2,397,288 shares. The stock had previously closed at $3.90.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on CMPX shares. Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Jefferies Financial Group upped their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday. Leerink Partners cut Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. Finally, D. Boral Capital restated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Compass Therapeutics has an average rating of “Moderate Buy” and an average target price of $11.17.

Compass Therapeutics Price Performance

The stock has a market cap of $502.20 million, a price-to-earnings ratio of -9.86 and a beta of 1.17. The stock’s 50-day moving average is $2.12 and its 200 day moving average is $1.74.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Analysts anticipate that Compass Therapeutics, Inc. will post -0.35 EPS for the current year.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC raised its position in shares of Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after purchasing an additional 112,614 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Compass Therapeutics by 921.6% during the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after purchasing an additional 356,352 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Compass Therapeutics by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after purchasing an additional 19,095 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Compass Therapeutics by 99.7% during the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after purchasing an additional 70,200 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Compass Therapeutics during the 3rd quarter worth approximately $79,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.